
The senior academic at the University of Sydney provided perspective on the role of CNM-Au8 in MS among a crowded treatment landscape, and the need for adjuvant treatments that address lingering lesion burden. [WATCH TIME: 3 minutes]
Senior academic at the University of Sydney.
The senior academic at the University of Sydney provided perspective on the role of CNM-Au8 in MS among a crowded treatment landscape, and the need for adjuvant treatments that address lingering lesion burden. [WATCH TIME: 3 minutes]
The senior academic at the University of Sydney discussed the reasons for using BC-LCLA and the modified MS Functional Composite in the phase 2 VISIONARY-MS trial. [WATCH TIME: 3 minutes]
The senior academic at the University of Sydney provided perspective on the promising findings of the phase 2 VISIONARY-MS study of CNM-Au8 in relapsing multiple sclerosis. [WATCH TIME: 6 minutes]
Published: May 12th 2023 | Updated:
Published: May 15th 2023 | Updated:
Published: May 22nd 2023 | Updated: